Chris Anigeron Rallis Sells 2,114 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis sold 2,114 shares of the business’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of C$10.97, for a total value of C$23,190.58.

Fennec Pharmaceuticals Stock Performance

Shares of FRX stock traded up C$0.29 on Friday, hitting C$15.10. 100 shares of the stock traded hands, compared to its average volume of 904. The company has a debt-to-equity ratio of 881.09, a current ratio of 4.84 and a quick ratio of 10.17. Fennec Pharmaceuticals Inc. has a 1-year low of C$9.27 and a 1-year high of C$15.43. The company’s fifty day moving average is C$13.22 and its 200 day moving average is C$12.18. The company has a market capitalization of C$408.30 million, a PE ratio of -14.95 and a beta of 0.35.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.